2. Andrew Fire, SiQun Xu, Mary K. Montgomery, Steven A. Kostas, Samuel E
Andrew Fire, SiQun Xu, Mary K. Montgomery, Steven A. Kostas, Samuel E. Driver and Craig C. Mello
Nature 391, (19 February 1998)

4. Ann E. Rougvie
Nature Reviews Genetics 2, (September 2001)

10. Table 1
The role of microRNAs in cancers
microRNAs Tumorigenesis
miR-9 Neuroblastoma
miR-10b Breast cancer
miR-15, miR-15a Leukemia, pituitary adenoma
miR-16, miR Leukemia, pituitary adenoma
miR-17-5p, miR Lung cancer, lymphoma
miR-20a Lymphoma, lung cancer
miR-21 Breast cancer, cholangiocarcinoma, head & neck cancer, leukemia, cervical cancer, Pancreatic cancer
miR-29, miR-29b Leukemia, cholangiocarcinoma
miR-31 Colorectal cancer
miR-34a Pancreatic cancer, Neuroblastoma
miR-96 Colorectal cancer
miR-98 Head & neck cancer
miR Pancreatic cancer
miR Leukemia, pancreatic cancer
miR-125a, miR-125b Neuroblastoma, breast cancer
miR Glioblastoma
miR-133b Colorectal cancer
miR-135b Colorectal cancer
miR Colon cancer, cervical cancer
miR Breast cancer, colorectal cancer
miR Thyroid carcinoma
miR Breast cancer, leukemia, pancreatic cancer
miR-181, miR-181a, miR-181c Leukemia, glioblastoma, thyroid carcinoma
miR Colorectal cancer
miR Neuroblastoma
miR-196a-2 Pancreatic cancer
miR Glioblastoma, thyroid carcinoma, Pancreatic cancer
miR Thyroid carcinoma
miR Leukemia
miR Pancreatic cancer
miR Pancreatic cancer
let-7, let-7a, let-7a-1, let-7a-3 Lung cancer, colon cancer
Mol Cancer. 2007; 6: 60.
Published online 2007 September 25. doi: /
Copyright © 2007 Cho; licensee BioMed Central Ltd.

11. Cell  , DOI: ( /j.cell )

17. Steven M. Johnson , Helge Grosshans , Jaclyn Shingara , Mike Byrom , Rich Jarvis , Angie Cheng , Emmanuel Labouri...
RAS Is Regulated by the let-7 MicroRNA Family
Cell, Volume 120, Issue 5, 2005,

18. Steven M. Johnson , Helge Grosshans , Jaclyn Shingara , Mike Byrom , Rich Jarvis , Angie Cheng , Emmanuel Labouri...
RAS Is Regulated by the let-7 MicroRNA Family
Cell, Volume 120, Issue 5, 2005,

19. Let-7g impairs proliferation and enhances cell death.
Let-7g impairs proliferation and enhances cell death. (A) LKR13-Tet-On-KRAB-TE-empty and -let-7g cells were plated (5 × 105 cells per plate). Twelve hours later, cells were placed in the presence/absence of 5 μg/ml doxycycline. Forty-eight hours later, images were taken by phase contrast microscopy. (B) Small RNA Northern blot analysis was performed against let-7g and Glutamine tRNA in LKR13-Tet-On-KRAB-TE-empty, -miR-15b, and -let-7g (see SI Text for details) cells in the presence or absence of 5 μg/ml doxycycline.
Kumar M S et al. PNAS 2008;105:
©2008 by National Academy of Sciences

20. Let-7g-induced tumors maintain overexpression and target suppression.
Let-7g-induced tumors maintain overexpression and target suppression. (A) Small RNA Northern blotting was performed against let-7g and Glutamine tRNA in LKR13-Tet-On-KRAB-TE-empty and -let-7g tumors generated from mice treated with or without doxycycline in the drinking water as described above. (B) Western blot analysis was performed in LKR13-Tet-On-KRAB-TE-empty and -let-7g tumors generated from mice treated with doxycycline in the drinking water as described above.
Kumar M S et al. PNAS 2008;105:
©2008 by National Academy of Sciences

21. K-RasG12D substantially rescues let-7g-mediated tumor suppression.
K-RasG12D substantially rescues let-7g-mediated tumor suppression. (A) LKR13-Tet-On-KRAB-TE-miR-15b and -let-7g cells were infected with pBabe.Zeo.empty, K-RasG12D, and HMGA2 and Western blot analysis was performed. (B and C) LKR13-Tet-On-KRAB-TE-let-7g cells infected with pBabe.Zeo.K-RasG12D (B) or HMGA2 (C) were prepared and injected (106 cells per injection) into immune-compromised mice. Mice were treated and tumors were measured as above. Values are mean ± SEM (n = 6).
Kumar M S et al. PNAS 2008;105:
©2008 by National Academy of Sciences

27. miR-26a facilitates gliomagenesis in vivo.
miR-26a facilitates gliomagenesis in vivo. (A) Kaplan-Meier curves demonstrating symptom-free survival for P/Z, P/26a, P/Cre, and P/26a/Cre mice (n = 23, 19, 14, and 17 respectively; [*] P < 0.05). The percentages of tumors exhibiting WHO grade II, grade III, and grade IV histological features are also shown for each genotype. (B) Kaplan-Meier curves demonstrating symptom-free survival for P/26a mice with and without detectable immunostaining for GFP reporter (n = 11 and 8 respectively; [*] P < 0.05). Histological grades for tumors in the P/26a GFP+ and P/26a GFP− groups are also shown.
Huse J T et al. Genes Dev. 2009;23:
©2009 by Cold Spring Harbor Laboratory Press

28. miR-26a represses PTEN expression in murine gliomas.
miR-26a represses PTEN expression in murine gliomas. Grade IV tumors from P/Z (A–C), P/26a (D–F), and P/Cre (G–I) mice. H&E staining is shown in A, D, and G; immunostaining for PTEN is shown in B, C E, F, H, and I. C, F, and I are enlargements at 5× magnification of the regions designated in by dashed boxes in B, E, and H, respectively (bars, 400 μm). Arrows indicate tumors on H&E staining. Red and blue dots are orientation guides. (J) Quantification of PTEN immunostaining for two tumors in each genotype (see the Materials and Methods); units are arbitrary. (*) P < 0.05.
Huse J T et al. Genes Dev. 2009;23:
©2009 by Cold Spring Harbor Laboratory Press